Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Effect of spinal tap test on the performance of sit-to-stand, walking, and turning in patients with idiopathic normal pressure hydrocephalus.

Bovonsunthonchai S, Witthiwej T, Ngamsombat C, Sathornsumetee S, Vachalathiti R, Muangpaisan W, Hengsomboon P, Thong-On S, Jankhum S, Yangyoo P.

Nagoya J Med Sci. 2018 Feb;80(1):53-60. doi: 10.18999/nagjms.80.1.53.

2.

Brainstem dysfunction heralding disseminated cryptococcosis.

Srivanitchapoom P, Pitakpatapee Y, Sitthinamsuwan P, Sathornsumetee S.

Clin Neurol Neurosurg. 2018 Apr;167:62-64. doi: 10.1016/j.clineuro.2018.02.015. Epub 2018 Feb 12.

PMID:
29454181
3.

Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.

Saesoo S, Sathornsumetee S, Anekwiang P, Treetidnipa C, Thuwajit P, Bunthot S, Maneeprakorn W, Maurizi L, Hofmann H, Rungsardthong RU, Saengkrit N.

Colloids Surf B Biointerfaces. 2018 Jan 1;161:497-507. doi: 10.1016/j.colsurfb.2017.11.003. Epub 2017 Nov 8.

PMID:
29128836
4.

Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis.

Sanvoranart T, Supokawej A, Kheolamai P, U-Pratya Y, Poungvarin N, Sathornsumetee S, Issaragrisil S.

Tumour Biol. 2016 Nov;37(11):14949-14960. Epub 2016 Sep 20.

PMID:
27651158
5.

High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.

Sathornsumetee S, Cheunsuchon P, Sangruchi T.

World Neurosurg. 2016 Jul;91:518-523.e1. doi: 10.1016/j.wneu.2016.02.069. Epub 2016 Mar 4.

PMID:
26960282
6.

Teaching NeuroImages: Erdheim-Chester disease (polyostotic sclerosing histiocytosis).

Srivanitchapoom P, Sathornsumetee S.

Neurology. 2015 Sep 8;85(10):e79-80. doi: 10.1212/WNL.0000000000001911. No abstract available.

PMID:
26346832
7.

Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service.

Chawalparit O, Sangruchi T, Witthiwej T, Sathornsumetee S, Tritrakarn S, Piyapittayanan S, Chaicharoen P, Direksunthorn T, Charnchaowanish P.

J Med Assoc Thai. 2013 Oct;96(10):1365-73.

PMID:
24350420
8.

Diagnostic performance of perfusion MRI in differentiating low-grade and high-grade gliomas: advanced MRI in glioma, A Siriraj project.

Direksunthorn T, Chawalparit O, Sangruchi T, Witthiwej T, Tritrakarn SO, Piyapittayanan S, Charnchaowanish P, Pornpunyawut P, Sathornsumetee S.

J Med Assoc Thai. 2013 Sep;96(9):1183-90.

PMID:
24163995
9.

Value of diffusion tensor imaging in differentiating high-grade from low-grade gliomas.

Piyapittayanan S, Chawalparit O, Tritakarn SO, Witthiwej T, Sangruchi T, Nunta-Aree S, Sathornsumetee S, Itthimethin P, Komoltri C.

J Med Assoc Thai. 2013 Jun;96(6):716-21.

PMID:
23951830
10.

ALS Untangled No. 20: the Deanna protocol.

ALSUntangled Group, Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Review. No abstract available.

PMID:
23638638
11.

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Reardon DA, Herndon JE 2nd, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ.

Br J Cancer. 2012 Oct 23;107(9):1481-7. doi: 10.1038/bjc.2012.415. Epub 2012 Oct 4.

12.

Siriraj Acute Stroke Unit: 10 years experience.

Chinwatanakul S, Boonyapisit K, Pornsriniyom D, Proyoonwiwat N, Senanarong V, Chaisevikul R, Danchaivijitr C, Chotinaiwatarakul W, Sathornsumetee S, Poungvarin N.

J Med Assoc Thai. 2012 Feb;95 Suppl 2:S235-44.

PMID:
22574555
13.

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE 2nd, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS.

J Neurooncol. 2012 Jul;108(3):499-506. doi: 10.1007/s11060-012-0848-x. Epub 2012 Mar 10.

14.

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS.

Cancer. 2012 Oct 1;118(19):4759-67. doi: 10.1002/cncr.26541. Epub 2012 Feb 27.

15.

Molecularly targeted therapy in neuro-oncology.

Sathornsumetee S, Rich JN.

Handb Clin Neurol. 2012;104:255-78. doi: 10.1016/B978-0-444-52138-5.00018-9. Review. No abstract available.

PMID:
22230448
16.

Twisted tango: brain tumor neurovascular interactions.

Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN.

Nat Neurosci. 2011 Oct 26;14(11):1375-81. doi: 10.1038/nn.2955. Review.

17.

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.

Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ.

J Neurooncol. 2012 Mar;107(1):213-21. doi: 10.1007/s11060-011-0740-0. Epub 2011 Oct 14.

18.

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS.

J Neurooncol. 2011 Dec;105(3):621-7. doi: 10.1007/s11060-011-0631-4. Epub 2011 Jul 9.

19.

Therapeutic strategies to target multiple kinases in glioblastoma.

Sathornsumetee S.

Anticancer Agents Med Chem. 2011 Oct;11(8):700-11. Review.

PMID:
21707500
20.

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA.

Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.

21.

Medical oncology: treatment and management of malignant gliomas.

Park DM, Sathornsumetee S, Rich JN.

Nat Rev Clin Oncol. 2010 Feb;7(2):75-7. doi: 10.1038/nrclinonc.2009.221. No abstract available.

PMID:
20118976
22.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS.

Br J Cancer. 2009 Dec 15;101(12):1986-94. doi: 10.1038/sj.bjc.6605412. Epub 2009 Nov 17.

23.

Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN.

Cancer Cell. 2009 Jun 2;15(6):501-13. doi: 10.1016/j.ccr.2009.03.018.

24.

Targeting multiple kinases in glioblastoma multiforme.

Sathornsumetee S, Reardon DA.

Expert Opin Investig Drugs. 2009 Mar;18(3):277-92. doi: 10.1517/13543780802692603 . Review.

PMID:
19243279
25.

Designer therapies for glioblastoma multiforme.

Sathornsumetee S, Rich JN.

Ann N Y Acad Sci. 2008 Oct;1142:108-32. doi: 10.1196/annals.1444.009. Review.

PMID:
18990124
26.

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.

Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260.

27.

Targeting cancer stem cells through L1CAM suppresses glioma growth.

Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN.

Cancer Res. 2008 Aug 1;68(15):6043-8. doi: 10.1158/0008-5472.CAN-08-1079.

28.

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS.

Neuro Oncol. 2008 Jun;10(3):330-40. doi: 10.1215/15228517-2008-003. Epub 2008 Mar 21.

29.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
30.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN.

J Clin Oncol. 2008 Jan 10;26(2):271-8. doi: 10.1200/JCO.2007.13.3652.

31.

Diagnosis and treatment of high-grade astrocytoma.

Sathornsumetee S, Rich JN, Reardon DA.

Neurol Clin. 2007 Nov;25(4):1111-39, x. Review.

PMID:
17964028
32.

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

J Clin Oncol. 2007 Oct 20;25(30):4722-9.

PMID:
17947719
33.

Molecularly targeted therapy for malignant glioma.

Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN.

Cancer. 2007 Jul 1;110(1):13-24. Review.

34.

Neurofibromatosis type 2.

Sathornsumetee S, DesJardins A, Reardon DA, Rich JN, Vredenburgh JJ.

Neurology. 2007 Mar 27;68(13):E14. No abstract available.

PMID:
17389295
35.

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.

Clin Cancer Res. 2007 Feb 15;13(4):1253-9.

36.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA.

J Neurooncol. 2007 May;83(1):53-60. Epub 2007 Jan 24.

PMID:
17245623
37.

Malignant glioma drug discovery - targeting protein kinases.

Sathornsumetee S, Vredenburgh KA, Lattimore KP, Rich JN.

Expert Opin Drug Discov. 2007 Jan;2(1):1-17. doi: 10.1517/17460441.2.1.1.

PMID:
23496034
38.

Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.

Sathornsumetee S, Rich JN.

Drugs Today (Barc). 2006 Oct;42(10):657-70. Review.

PMID:
17136225
39.

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ.

Neuro Oncol. 2007 Jan;9(1):70-4. Epub 2006 Nov 15.

40.

New approaches to primary brain tumor treatment.

Sathornsumetee S, Rich JN.

Anticancer Drugs. 2006 Oct;17(9):1003-16. Review.

PMID:
17001172
41.

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.

Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN.

Cancer Res. 2006 Sep 1;66(17):8722-30.

42.

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN.

Cancer Res. 2006 Aug 15;66(16):7843-8.

43.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
44.

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8.

45.

Friday night palsy: an unusual case of brachial plexus neuropathy.

Sathornsumetee S, Morgenlander JC.

Clin Neurol Neurosurg. 2006 Feb;108(2):191-2. Epub 2005 Jan 13.

PMID:
16412841
46.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS.

J Clin Oncol. 2005 Dec 20;23(36):9359-68. Erratum in: J Clin Oncol. 2006 Mar 1;24(7):1224. Rich, Jeremy N Sr [corrected to Rich, Jeremy N]; Gururangan, Idharan [corrected to Gururangan, Sridharan].

PMID:
16361636
47.

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.

Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS.

Clin Cancer Res. 2005 Nov 15;11(22):8145-57.

48.

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS.

Cancer. 2005 Oct 1;104(7):1478-86.

49.

Chemotherapy and novel therapeutic approaches in malignant glioma.

Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS.

Front Biosci. 2005 Sep 1;10:2645-68. Review.

PMID:
15970525
50.

Parry-Romberg syndrome with fatal brain stem involvement.

Sathornsumetee S, Schanberg L, Rabinovich E, Lewis D Jr, Weisleder P.

J Pediatr. 2005 Mar;146(3):429-31.

PMID:
15756237

Supplemental Content

Loading ...
Support Center